There are currently 2865 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
NCT05529069
Recruiting
To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Mantle Cell Lymphoma, Non Hodgkin Lymphoma, Hematologic Malignancy
Register for Updates
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
NCT06191978
Recruiting
To find a recommended dose of ASTX727 (cedazuridine/decitabine) in combination with venetoclax for pediatric patients with relapsed AML.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
05/13/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia
Register for Updates
A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies
NCT04349436
Recruiting
This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, hepatic, heart, lung, or other solid organ transplantation or hematopoietic cell transplant and experiencing subsequent documented locally advanced or metastatic cutaneous malign... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Melanoma
Register for Updates
RLE Outcomes With Bilateral Implantation of Odyssey IOLs
NCT06979557
Recruiting
This study is a single center, ambispective study of visual outcomes after successful bilateral implantation of the Odyssey IOL. Subjects will be assessed at least 2 months postoperatively at a single visit. Clinical evaluations will include administration of the AIOLIS questionnaire, as well as measurement of visual acuities at distance, intermediate, and near, monocular (right eye) and binocular defocus curve, and refractive outcomes.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/13/2025
Locations: Mann Eye Institute, Houston, Texas
Conditions: Refractive Lens Exchange
Register for Updates
A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder
NCT06648655
Recruiting
TMP-301 has been shown in preclinical models to reduce consumption of alcohol and other addictive substances. It has been tested in healthy subjects and has been found to be safe and tolerated at doses predicted to be efficacious in alcohol use disorder. This study is being conducted to evaluate the safety, tolerability and efficacy of TMP-301 in patients with alcohol use disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/13/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Alcohol Use Disorder (AUD)
Register for Updates
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
NCT03203525
Recruiting
This phase I trial studies the side effects and best dose of combination chemotherapy and bevacizumab, and to see how well they work with the NovoTTF-100L(P) system in treating participants with cancer that has come back or does not respond to treatment and has spread to the liver. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, fluorouracil, pegylated liposomal doxorubicin hydrochloride, and temsirolimus, work in different ways to stop the growth of cancer cells, either by killing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver, Refractory Malignant Neoplasm
Register for Updates
Systems Biology of Early Atopy
NCT04798079
Recruiting
The goal of this study is to establish a birth cohort that collects prenatal and early life biosamples and environmental samples and rigorously phenotypes young children for food allergy and Atopic Dermatitis (AD) to identify prenatal and early life markers of high risk for food allergy and AD, as well as biological pathways (endotypes) that result in these conditions. Primary Objectives: * To study the role and interrelationships of established and novel clinical, environmental, biological, a... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
05/13/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Allergic Diseases, Food Allergy, Atopic Dermatitis
Register for Updates
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
NCT05742607
Recruiting
The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Millennium Research & Clinical Development, Houston, Texas
Conditions: Non Small Cell Lung Cancer
Register for Updates
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
NCT06430385
Recruiting
The primary purpose of this study is to evaluate the safety and tolerability of ION440.
Gender:
MALE
Ages:
Between 2 years and 65 years
Trial Updated:
05/13/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Register for Updates
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
NCT05660083
Recruiting
This is a research study to test the safety and effectiveness of using the drug alpelisib together with chemotherapy (nab-paclitaxel) and a drug called L-NMMA in patients with HER2 negative metastatic or locally advanced metaplastic breast cancer, who have not responded to previous treatments. Participants in this study in addition to the standard care chemotherapy will also receive the drug alpelisib and L-NMMA. The therapies will be administered every 3 weeks (1 cycle) until disease progressi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Houston Methodist Neal Cancer Center, Houston, Texas +1 locations
Conditions: HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer
Register for Updates
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
NCT05911763
Recruiting
This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape in each study country. Decision to initiate treatment with commercially available efanesoctocog alfa will be made by the treating... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/13/2025
Locations: Gulf States Hemophilia and Thrombophilia Center- Site Number : 8400029, Houston, Texas
Conditions: Hemophilia A
Register for Updates
SMP-3124LP in Adults With Advanced Solid Tumors
NCT06526819
Recruiting
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor
Register for Updates